Several of the most common chronic conditions are overwhelmingly female — yet they take an average of 7–10 years to diagnose. Not because they're rare, but because women's pain and symptoms have historically been under-investigated.
PCOS affects 1 in 8–10 women globally, making it the most prevalent endocrine disorder in women of reproductive age. Despite the name, you don't need to have cysts — the Rotterdam criteria requires just 2 of 3 features: irregular ovulation, elevated androgens, or polycystic-appearing ovaries on ultrasound. PCOS is a metabolic condition as much as a reproductive one. At its core is insulin resistance and androgen excess — and these two drivers create a feedback loop that disrupts ovulation, causes inflammation, raises cardiovascular risk, and significantly increases lifetime risk of type 2 diabetes. There are at least 4 distinct phenotypes, each with different drivers and management approaches.
Women with PCOS wait an average of 2 years and see 3 different clinicians before receiving a diagnosis (Gibson-Helm et al., 2017). Most are diagnosed only after presenting with infertility or severe acne — meaning the metabolic consequences have often been developing silently for years. PCOS in teenage girls is particularly under-recognised because irregular periods are dismissed as "normal for teens."
The 4 Phenotypes
All 3 Rotterdam criteria met. Strongest insulin resistance and highest metabolic risk. Responds well to insulin-sensitising approaches: low-GI diet, inositol, metformin.
Irregular cycles and elevated androgens, but no polycystic ovaries on ultrasound. Often missed because "no cysts" leads clinicians to dismiss PCOS.
Elevated androgens and polycystic ovaries, but regular ovulation. Periods are regular so diagnosis is often delayed. Predominantly androgenic presentation: acne, hirsutism.
Irregular ovulation and polycystic ovaries, but normal androgens. The mildest metabolic phenotype. Often triggered by stress, rapid weight change, or thyroid dysfunction.
Symptoms
Evidence-based management
Endometriosis affects approximately 1 in 10 women of reproductive age, and up to 50% of women with infertility. It occurs when tissue similar to the uterine lining grows outside the uterus — on the ovaries, fallopian tubes, bowel, bladder, or peritoneum. This tissue responds to hormonal cycles just like the uterine lining — bleeding monthly but with no exit route, causing inflammation, scarring, and adhesions. Endometriosis is not just a period problem: it is now classified as a systemic inflammatory disease with immune, neurological, and gut involvement. It is not caused by retrograde menstruation alone — research points to genetic, epigenetic, immune, and environmental contributions.
The 7–10 year diagnostic delay is one of medicine's most glaring failures. Women visit their GP an average of 7 times before referral. Pain is routinely dismissed as "normal period pain," and many women are prescribed the contraceptive pill which suppresses — but does not treat — the underlying disease. Definitive diagnosis requires laparoscopy, though MRI and expert ultrasound can detect deep infiltrating disease. Painful periods are not normal.
Symptoms
Evidence-based management
Uterine fibroids (leiomyomas) are benign muscular tumours that grow in or around the uterus. By age 50, up to 70% of white women and 80% of Black women will have developed fibroids — making them extraordinarily common, yet routinely dismissed. Fibroids are estrogen and progesterone-sensitive: they grow during reproductive years and shrink after menopause. Their impact depends heavily on location: small fibroids in the uterine wall may be asymptomatic, while submucosal fibroids projecting into the uterine cavity cause severe bleeding and fertility problems even when small. The disparity in fibroid burden between Black and white women is one of the most stark examples of racial health inequity in women's medicine.
Symptoms
Evidence-based management
PMDD is a severe, disabling form of PMS that affects approximately 3–8% of women of reproductive age. It is classified in DSM-5 as a depressive disorder — not simply "bad PMS." The hallmark is cyclical, severe mood symptoms (depression, anxiety, rage, suicidal ideation) that appear in the luteal phase and resolve reliably within a few days of menstruation starting. PMDD is not caused by abnormal hormone levels — women with PMDD have normal estrogen and progesterone. The disorder arises from an abnormal neurological sensitivity to normal hormonal fluctuations — specifically to the drop in progesterone and its conversion to allopregnanolone, which normally has a calming GABA-activating effect. In PMDD, this pathway paradoxically causes anxiety and dysphoria.
PMDD is missed because symptoms — depression, anxiety, rage, paranoia — look like psychiatric conditions when described outside their cyclical context. The critical diagnostic feature is the timing: symptoms appear in the luteal phase and resolve within 3 days of menstruation. Tracking symptoms prospectively for 2 cycles using the DRSP or PME diary is the gold-standard diagnostic method. A blood test cannot diagnose PMDD — hormone levels are normal. Any woman with cyclical mood symptoms that reliably disappear after her period starts should be investigated for PMDD, not just treated for depression.
Symptoms
Evidence-based management
Hashimoto's thyroiditis is an autoimmune condition in which the immune system produces antibodies (anti-TPO and anti-thyroglobulin) that gradually destroy thyroid tissue, leading over time to hypothyroidism. Hashimoto's is the most common autoimmune condition globally, affecting an estimated 5% of the general population and up to 10% of women over 60. The critical distinction from simple hypothyroidism is that Hashimoto's is an immune disorder — treating the thyroid hormone deficiency with levothyroxine does not address the underlying autoimmune attack. Women with Hashimoto's have a significantly higher risk of other autoimmune conditions, including type 1 diabetes, coeliac disease, lupus, and rheumatoid arthritis.
Symptoms
Evidence-based management
Autoimmune diseases — where the immune system attacks the body's own tissues — affect approximately 8% of the global population. Strikingly, 78–80% of all autoimmune disease cases occur in women. This reflects fundamental biological differences in immune regulation driven by sex chromosomes, estrogen signalling, and the microbiome. Women have more robust immune responses than men — an evolutionary advantage for fighting infection, but a vulnerability to immune misdirection. Estrogen amplifies antibody production and inflammatory cytokines; testosterone has immunosuppressive properties. The X chromosome carries over 800 immune-related genes, and women (with two X chromosomes) have greater immunological complexity, increasing the risk of dysregulation.
Women with autoimmune conditions are diagnosed an average of 4.6 years later than men with the same condition — and are 2.5 times more likely to be initially diagnosed with a mental health condition (Duszynski-Goodman 2021). Lupus (SLE) has the most documented diagnostic gap: women are sent home from emergency departments more often despite identical symptom scores. Fibromyalgia — now understood to involve central immune sensitisation — is diagnosed predominantly in women and routinely dismissed as psychosomatic. Vague, multisystem symptoms in women deserve investigation, not dismissal.
Symptoms
Evidence-based management
Symptom timelines are your most powerful tool. Document when symptoms occur in your cycle, their severity, and how they affect daily function. The pattern is the diagnosis.
Standard panels miss most of these conditions. Each condition has specific markers — see the advocate box for each condition for the exact tests to ask for by name.
General practitioners are trained in common presentations. For complex conditions like endometriosis or Hashimoto's, specialist centres provide meaningfully better outcomes — you can ask for a referral.